Overview of enzyme inhibitors and anti-androgens in prostatic cancer.

摘要: Surgical castration and estrogen therapy for prostate cancer were developed in 1941, have been shown to improve both quality of life survival. Little change the therapeutics has occurred over subsequent three decades. In 1970s, progestational anti-androgens, ketoconazole flutamide, introduced as androgen-blocking agents, block at least partially adrenal testicular androgens. Gonadotropin-releasing hormone (GnRH) agonists 1980s produce medical without cardiac cerebrovascular risks standard dose estrogen. 1980s, large-scale, multicenter, double-blind studies done compare effect combined androgen blockade, using multiple drugs, single-drug blockade gonadal with regard time progression survival stage D2 cancer. These test theories regarding role androgens their effects on androgen-sensitive tumor clones The theory clonal heterogeneity, particularly sensitivity, led continuation major controversies about management cancer: Is more effective than alone? What is optimal secondary or tertiary relapsed cancer? there any advantage start compared sequential first, then relapse?